Aurinia Pharmaceuticals Inc. (AUPH)
Aurinia Pharmaceuticals Inc. (AUPH) from its SEC filings: 2025 revenue $283.1 million (+20% vs the year before), net margin 102%, free cash flow $135.7 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $283.1 million |
| Revenue growth | +20% |
| Net income | $287.2 million |
| Net margin | 101.5% |
| Free cash flow | $135.7 million |
| Diluted EPS | $2.07 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +19% |
| Cash | $179.7 million |
| Share count, 1 year | +1% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.